Cardiac Amyloidosis (CA) is a life-threatening and progressive cause of heart failure that is often underdiagnosed. Early and accurate diagnosis of cardiac amyloidosis is crucial for the implementation of appropriate patient care and is now more important than ever, given the availability of new therapies.
Multimodality imaging remains a cornerstone of diagnosis and monitoring of cardiac amyloidosis. High clinical suspicion coupled with a good understanding of key findings on the first line test of echocardiocardiography should lead to further imaging investigations, such as cardiac MRI (CMR) and bone scintigraphy. These techniques have revolutionised our understanding of the disease and led to changes in patient care. However, high clinical suspicion and accurate interpretation of the imaging findings is essential in distinguishing cardiac amyloidosis from other causes of left ventricular hypertrophy.
Developed with support from the Pfizer Global Medical Grants Program, this package includes two modules. The Educational content introduces cardiac amyloidosis and its appearance on different imaging modalities. The Training module will allow you to test your knowledge of imaging features of cardiac amyloidosis and its differentials on real-world echo and CMR cases.
Teaching material with real-world cases giving an overview of multimodality imaging in cardiac amyloidosis
A series of real-world cases for you to practise spotting Cardiac Amyloidosis, with immediate feedback provided on each case.
You must sign in or register to access this package